Dr. Germain on Scientific Rationale Behind Bortezomib/Fulvestrant for HR+ Breast Cancer

Video

Doris Germain, PhD, ‎associate professor at Mount Sinai Cancer Institute, discusses the scientific rationale behind a clinical trial comparing fulvestrant alone with bortezomib plus fulvestrant for the treatment of hormone receptor-positive metastatic breast cancer.

Doris Germain, PhD, ‎associate professor at Mount Sinai Cancer Institute, discusses the scientific rationale behind a clinical trial comparing fulvestrant alone with bortezomib plus fulvestrant for the treatment of hormone receptor-positive metastatic breast cancer.

Fulvestrant promotes the aggregation of the newly synthesized estrogen-receptor (ER) in the cytoplasm, which leads to cell death. However, this effect is limited as a result of the proteasome.

By combining fulvestrant with the proteasome inhibitor, bortezomib, the fulvestrant-mediated aggregation is enhanced without blocking the degradation of the ER in the nucleus. This induces tumor regression. The impact of the bortezomib/fulvestrant combination was further investigated in a phase II clinical trial led by Kerin Adelson, MD.

Related Videos
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Video 1 - "HR+/HER2- Early-Stage Breast Cancer: Background and Risk Stratification "